For its first fiscal quarter (ending March 31), Neogenomics Inc (NASDAQ: NEO) has reported E.P.S. of $-0.21 compared to $-0.25 a year ago. This performance was $-0.22 short of the consensus estimate of $0.01. For the latest four quarters through March 31, E.P.S. were $-0.66 compared to $-1.01 a year ago.
Recent Price Action
Neogenomics Inc (NASDAQ: NEO) stock closed at $13.92 on 4/30/24 after a large decline of -8.5%. Moreover, trading volume in this decline was exceptionally high at 260% of normal. The stock has performed in line with the market over the last nine months and has risen 3.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, NEO is expected to continue to be Value Creation neutral.
Neogenomics has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Neogenomics has a poor Appreciation Score of 24 but a slightly positive Power Rating of 64, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment